BGPT: Paper Review: 14-3-3 binding maintains the Parkinson’s associated kinase LRRK2 in an inactive state

Explore by Goal

Quick Explanation Copied

Core mechanism (from the paper)

A 14-3-3 dimer binds phosphorylated S910/S935 plus a COR-A/B (Roc-COR) interface, dual-site anchoring that stabilizes an autoinhibited/inactive monomeric LRRK2 and reduces kinase access. Disrupting either interface weakens binding and decreases inhibition; active-conformation stabilizers (type I inhibitor MLi-2) reduce 14-3-3 binding and promote dephosphorylation of S910/S935 in cells.

Read the structure/functional logic directly in the Methods+Results-linked claims of the paper:

Long Explanation

BGPT • Rigorous paper review

14-3-3 binding maintains the Parkinson’s associated kinase LRRK2 in an inactive state

DOI: 10.1038/s41467-025-62337-1 • EMDB/PDB: EMD-45609 / 9CI3

Visual thesis map (what the authors claim)

Study design (what was measured)

Module	What they did	What it supports
Structure	Cryo-EM of LRRK2:14-3-3 (γ), with BS3 cross-linking to improve homogeneity; report 3.96 Å global map and 3.87 Å local Roc-COR:14-3-3; deposit EMDB/PDB.	Direct spatial basis for pS910/pS935 + COR dual-site anchoring and kinase-inactive conformation.
Binding & sites	Co-IP and MST (reported K_D ~212 nM for WT LRRK2–14-3-3γ; phospho-site mutants abolish binding; COR interface mutants weaken binding).	Primary vs secondary interface contributions to affinity.
Inhibition logic	In vitro kinase assay using Rab10 substrate; Rab10 phosphorylation inhibited by 14-3-3 in concentration-dependent manner; interface mutants reduce inhibition.	Functional coupling between binding mode and kinase inhibition.
Conformation switching	MST with type I (MLi-2) vs type II (Rebastinib) inhibitors; cell assays for pS910/pS935 and co-IP of 14-3-3.	Evidence that active-conformation stabilizers destabilize 14-3-3 binding and trigger dephosphorylation at S910/S935.
PD mutations	Mutations at Roc/COR interfaces (e.g., R1628P, R1728H) and other PD variants; report increased kinase activity and weakened inhibition / 14-3-3 binding for specific mutants.	Mechanistic bridge from genotype → complex destabilization → higher kinase signaling.

Evidence base for the above: the paper’s structural and biochemical workflow and numeric outcomes are described throughout Results/Methods and data availability sections.

Binding affinity: WT LRRK2–14-3-3γ (MST)

KD is reported as ~212 nM for WT by MST.

Functional inhibition: Rab10 phosphorylation blocked by 14-3-3 (in vitro)

The paper reports ~50% Rab10 phosphorylation inhibition with WT and ~25% inhibition for interface-disrupting mutants (primary sites S910/S935 and secondary COR interface residues, plus some 14-3-3 interface residues).

Conformation switch: type I inhibitor (MLi-2) destabilizes 14-3-3 binding and lowers pS910/pS935

The paper states that in cells, MLi-2 causes a ~19-fold reduction in pS910/pS935 and ~7-fold decrease in co-IP 14-3-3, while Rebastinib has no significant effect on these readouts.

PD mutations: some destabilize 14-3-3 binding and reduce inhibition

The paper reports: R1441G causes ~10-fold reduction in pS910 and ~15-fold in pS935; R1728H shows ~1.6-fold reduction in pS935, with additional context that COR interface destabilization reduces 14-3-3 binding and inhibition.

Mechanistic interpretation (with epistemic humility)

Known from the paper (high confidence)

The cryo-EM structure supports a 1:1 stoichiometry between an LRRK2 monomer and a 14-3-3 dimer in the autoinhibited/inactive complex, with global map resolution ~3.96 Å and local Roc-COR:14-3-3 ~3.87 Å.
Dual-site engagement is experimentally localized to primary phospho-sites pS910/pS935 and a secondary COR-A/B interface, and the paper argues that this geometry constrains LRR domain motion and occludes kinase access in the inactive conformation.
Disrupting either interface weakens binding and reduces inhibition of LRRK2 kinase activity (Rab10 phosphorylation), establishing a functional coupling between binding architecture and inhibition.

Inferred/interpretive claims (moderate confidence)

The paper proposes that type I inhibitors stabilize an active conformation that disrupts COR:14-3-3 compatibility and thus reduces 14-3-3 binding and promotes S910/S935 dephosphorylation. This is strongly supported by the differential effects (MLi-2 vs Rebastinib) on binding affinity and pS levels, but it remains a model rather than a directly visualized active-state complex.
The authors further argue that 14-3-3 binding maintains a “dormant state” by preventing LRRK2 dimerization/oligomerization via overlap of interfaces, but the presented data combine structural interface overlap reasoning with SEC-MALS/MALS-like assessments using reconstituted purified complexes. Physiological oligomerization dynamics in native membranes are not fully resolved here.

Critical appraisal (biases, limitations, what could change)

Potential limitation set

Complex formation strategy: BS3 cross-linking is used to improve cryo-EM density for 14-3-3, which can bias the observed conformational ensemble toward cross-linkable states. The paper partially addresses this via additional checks (e.g., in vivo co-expression/purification), but ensemble bias remains a general concern for cross-link-assisted structural capture.
Unresolved/absent segments: ARM/ANK/LRR regions (N-terminal residues 1–906) are not observed in density, and some loops are low-resolution/unmodeled. Mechanistic claims about how these regions behave in cells are therefore not directly proven by this structure alone.
Isoform mixture in purified samples: Although recombinant 14-3-3γ is used, mass spectrometry indicates multiple 14-3-3 isoforms in the complex (likely co-purified endogenous isoforms from mammalian expression). That complicates strict isoform-specific generalization. The paper also reports in vivo complex formation via co-expression to support physiological relevance, but isoform composition-specific biophysics still needs caution.
In vitro vs cellular context: The most direct inhibition link is in purified protein kinase assays. Cellular outcomes are measured for phosphosite levels and co-IP, but the full spatiotemporal activation cycle (including lysosome/stress triggers and membrane-dependent regulation) is not fully reconstructed in this study.

What would most strongly disprove/reshape the model?

If active-state LRRK2 retained similar 14-3-3 affinity and did not drive S910/S935 dephosphorylation in cells, the active-state disruption portion of the mechanism would be weakened. (The current paper supports it differentially via MLi-2 vs Rebastinib, but direct structural capture of the active-state complex is not shown.)
If interface-disrupting mutations did not reduce inhibition of Rab10 phosphorylation despite weakening binding, the causal linkage between dual-site anchoring and inhibition would be challenged. (The paper reports reduced inhibition with primary/secondary interface mutations.)

Where this fits in the broader LRRK2–14-3-3 landscape

14-3-3 proteins are classic phosphoserine/phosphothreonine-binding adaptors whose interactions generally depend on phosphomotifs engaging conserved grooves.

Practical takeaways for mechanistic biologists

Dual-site anchoring (phospho-sites + COR interface) provides concrete mutational targets: disrupt either site to test whether kinase inhibition collapses in the same way across cellular contexts.
Conformation-dependent binding implies that phosphosite biomarkers (pS910/pS935) are more than occupancy markers—they likely report the regulatory state of the inactive complex vs active conformation.

Author-review links (bespoke BGPT pages)

Feedback:

Updated: April 12, 2026